Heat-activated nanomedicine formulation improves the anticancer potential of the HSP90 inhibitor luminespib in vitro

Abstract The heat shock protein 90 inhibitor, luminespib, has demonstrated potent preclinical activity against numerous cancers. However, clinical translation has been impeded by dose-limiting toxicities that have necessitated dosing schedules which have reduced therapeutic efficacy. As such, lumine...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Brittany Epp-Ducharme, Michael Dunne, Linyu Fan, James C. Evans, Lubabah Ahmed, Pauric Bannigan, Christine Allen
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
R
Q
Acceso en línea:https://doaj.org/article/32a868415be64939b8264f6b7ef89b9c
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!